Introduction {#Sec1}
============

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world, affecting 740,000 people annually \[[@CR1]\]. The incidence of HCC has been rising due to an increase in hepatitis-C virus infections \[[@CR2]--[@CR4]\]. Curative resection or ablation is indicated for early HCC \[[@CR5]--[@CR7]\]. However, the 3-year recurrence rate after curative treatment in the general population is 50 % \[[@CR8], [@CR9]\]. Furthermore, the recurrence rate is \>70 % in hepatitis C virus-positive patients \[[@CR10]\]. Recurrence within 2 years of curative treatment is mainly associated with intrahepatic metastasis, whereas multicentric de novo carcinogenesis (second primary HCC) is the common cause of recurrence after 2 years \[[@CR11], [@CR12]\]. Most importantly, no effective approach has been established to prevent HCC recurrence \[[@CR13]--[@CR15]\].

The concept of chemoprevention using retinoids has been proposed as a means to delay or prevent recurrence after treatment of HCC \[[@CR16]\]. Peretinoin \[(2*E*,4*E*,6*E*,10*E*)-3,7,11,15-Tetramethylhexadeca-2,4,6,10,14-pentaenoic acid\] is a synthetic retinoid with a retinoic acid receptor and retinoid X receptor agonist activity \[[@CR17]\]. Peretinoin is known to suppress tumor growth in the human liver by inducing apoptosis and differentiation of liver cancer cells \[[@CR18], [@CR19]\]; it also acts by increasing p21 protein levels and reducing cyclin D1 levels to inhibit proliferation of these cells \[[@CR20]\]. Recently, a small-scale, randomized study has demonstrated that peretinoin (600 mg/day) reduced HCC recurrence and increased the survival of patients treated with curative therapy \[[@CR21], [@CR22]\].

Multiple other studies have evaluated the safety of peretinoin dosages. A phase I study evaluated the proportionality of blood concentration using three peretinoin doses (300, 600, and 900 mg/day) \[[@CR23]\]. Based on non-clinical studies and phase I studies, a dose of 300 mg/day was assumed to result in a drug concentration in the liver sufficient to produce medicinal action (apoptosis and induction). The 900 mg/day dose resulted in unacceptable hypertension.

Based on these findings and the hypothesis that peretinoin efficacy saturates at 300 mg/day, this clinical study evaluated the efficacy and dose--response relationship of peretinoin in a randomized, double-blind, placebo-controlled study.

In Japan, approximately 70 % of HCC patients are HCV-positive, and there is a higher risk of HCC recurrence due to HCV than due to other causes of recurrence. To verify an inhibitory effect on recurrence in a population that is uniform in having a high risk of recurrence, this study was conducted in HCV-positive patients after having a complete response to treatment.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Patients were recruited from outpatient groups at 41 institutions in Japan. Patients with primary HCV-HCC or first recurrence successfully treated with resection or radiofrequency ablation were included in the study. HCC was diagnosed based on the finding of a typical vascular pattern (hypervascularity in the arterial phase and wash-out in the portal equilibrium phase) on dynamic CT, according to the Consensus-Based Clinical Practice Manual proposed by the Japan Society of Hepatology \[[@CR5]\]. Complete response was defined similarly to that of the modified Response Evaluation Criteria in Solid Tumors (modified RECIST) definition and required a diagnosis of a complete cure. Three independent radiologists reviewed all CT images to confirm complete cure. Eligibility criteria included: positive for serum hepatitis C virus RNA; Child-Pugh liver function class A or B (Table S1); platelet count ≥50000/µL; and age ≥20 years. Exclusion criteria included: positive for hepatitis B surface antigen; portal invasion with HCC; concurrent use of transcatheter arterial embolization/chemoembolization for curative treatment; use of other investigational drugs, antitumor drugs, interferon, or vitamin K2; uncontrollable blood pressure under drug therapy (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg); serious complications; allergy to retinoids or contrast agents for CT; past total gastric resection; and being pregnant or breastfeeding. This study was approved by the institutional review board at each center and conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written informed consent. The study protocol is registered at JAPIC Clinical Trials: JapicCTI-060250 (<http://www.clinicaltrials.jp/user/cteSearch.jsp>).

Study design {#Sec4}
------------

This study was a multicenter, parallel-group, double-blind, randomized, placebo-controlled study (Fig. S1). Patients who satisfied the eligibility criteria were assigned to receive peretinoin 600 mg/day, peretinoin 300 mg/day, or placebo at a 1:1:1 ratio. The randomization was centralized, and assignment to study groups was conducted by computer using the minimization method with adjustment for primary tumor/first recurrence and curative treatment (resection/ablation). Equal intra-institutional distribution was ensured. Patients orally ingested the assigned study drug twice daily for up to 96 weeks. Follow-up of individual patients was to be discontinued and study completion would occur when the number of events (HCC recurrence or death) reached 180--200. Patients visited the institutions once every 4 weeks during the study treatment period and once every 12 weeks thereafter. Treatment compliance was evaluated by pill counts. Use of antitumor drugs, interferon, vitamin K2, vitamin A, or an antiviral drug ribavirin was prohibited during the study duration. All those involved in this study, including patients, were blinded to the treatment regimen and a placebo identical in external appearance to the study drug was used.

Endpoints {#Sec5}
---------

The primary endpoint was recurrence-free survival (RFS), defined as the time from randomization to HCC recurrence or death from any cause, whichever occurred first. Abdominal dynamic CT was performed every 12 weeks. Tumor markers (α-fetoprotein, Lens culinaris agglutinin-reactive α-fetoprotein isoform, and protein induced by vitamin K absence or antagonist-II) were measured every 12 weeks. If tumor markers rapidly increased, abdominal dynamic CT was additionally performed. Recurrence of HCC was confirmed based on findings of hypervascularity (nodules enhanced in the arterial phase and washout in the late phase) by dynamic CT images. Recurrence of HCC was judged by three independent radiologists, who reviewed all dynamic CT images. The secondary endpoint was disease-free survival, which was defined as the time from randomization to HCC recurrence, death from any cause, or onset of secondary tumor, whichever occurred first. For safety assessments, incidences of adverse events were evaluated based on periodic examinations and tests. Laboratory tests were performed collectively at the central laboratory.

Statistical analysis {#Sec6}
--------------------

The primary comparison of this study was to examine the superiority of peretinoin (300 and 600-mg) to placebo by RFS. RFS was estimated and presented as survival curves for the treatment groups using the Kaplan--Meier method. Subsequently, the dose--response relationship of peretinoin was evaluated. A stratified log-rank test was performed according to the type of curative treatment (resection/ablation) in the pre-specified three sets of contrasts (Fig. S2). The contrast reflecting the hypothesis that the efficacy of peretinoin saturates at 300 mg/day was tested as the "primary comparison". To evaluate the dose--response relationship of peretinoin, tests were also performed for the two other sets of contrasts ("efficacy increases linearly" and "efficacy begins to increase at 600 mg/day"). The multiplicity of the three sets of contrasts was adjusted using a permutation test \[[@CR24]\].

Sample size was determined based on the primary aim. The number of events required when the clinically useful hazard ratio (HR) supporting a reduction in recurrence was around 0.60 with a 0.025, one-sided significance level, a 0.90 power, and a 2:1 patient ratio \[peretinoin (300 and 600-mg) vs. placebo\] was calculated using Freedman's formula \[[@CR25]\]. Based on 180 expected events and the 3-year mean duration of follow-up, 120 patients in each treatment group (360 patients in total) were required.

Hazard ratios and 95 % confidence intervals (CIs) for RFS in the peretinoin 600-mg or the 300-mg group vs. placebo group were calculated for the entire study period and at predefined intervals (within 1 year of randomization, at 1--2 years, and after 2 years) with Cox regression analyses using curative treatment as a covariate.

In exploratory, post-hoc, subgroup analysis, the Cox proportional-hazard model was used to evaluate the interaction between baseline characteristics and the effect of peretinoin (peretinoin 600-mg vs. placebo). Factors chosen as baseline characteristics were sex, age, HCC (primary or first recurrence), treatment (local ablation or surgical resection), number of tumor masses, tumor size, and Child-Pugh class.

Efficacy analysis was performed after excluding ineligible patients, patients whose efficacy data were missing, and patients who had never taken the study drug based on the intention-to-treat principle. A two-sided significance level of 0.05 was used. The analysis of disease-free survival was performed in the same manner as the RFS analysis. All patients who had taken the study drug at least once were included in the safety analysis set. Adverse events were classified according to Medical Dictionary for Regulatory Activities (MedDRA) Version 12.0. The dose--response relationship for safety was evaluated using the Cochran--Armitage test.

The independent data and safety monitoring committee performed an interim analysis twice in accordance with the study protocol as follows: first, safety was analyzed when approximately 60 patients had been in the study for at least 1 year; second, safety and efficacy were analyzed when the number of events reached approximately 100. The study was continued after these two interim analyses because none of the discontinuation criteria defined in the study protocol were applicable.

Results {#Sec7}
=======

Patients {#Sec8}
--------

Patients were recruited from March 14, 2005, through July 30, 2007. The study was terminated on August 27, 2009, because the target number of events (180--200) was achieved. The median follow-up period was 911 days (95 % CI 845--937 days). A total of 401 patients were randomized (Fig. [1](#Fig1){ref-type="fig"}). Patient characteristics were comparable among the three treatment groups (Table [1](#Tab1){ref-type="table"}). Patients aged ≥65 years accounted for about 70 % of the study population, and those who were Child-Pugh class A accounted for about 80 % of patients in each treatment group. The mean duration of the study treatment was 416 days (95 % CI 392--441 days) (600-mg group, 398 days; 300-mg group, 410 days; placebo group, 442 days). Of those who were included in the efficacy analysis, 368 patients (97.6 %) complied with the study treatment for at least 70 % of the time (96.0, 98.4, and 98.4 %, respectively). Fig. 1Flow diagram of study patientsTable 1Baseline characteristics of study patientsVariablePeretinoinPlacebo *n* = 127600 mg/day *n* = 124300 mg/day *n* = 126Number (%)Gender Male81 (65.3)73 (57.9)87 (68.5) Female43 (34.7)53 (42.1)40 (31.5)Age (year) \<6537 (29.8)38 (30.2)40 (31.5) 65--7563 (50.8)61 (48.4)57 (44.9) ≥7524 (19.4)27 (21.4)30 (23.6) Mean (SD)68.1 (7.1)68.2 (7.7)68.6 (7.8)BMI (kg/m^2^) \<2595 (76.6)98 (78.4)106 (83.5) ≥2529 (23.4)27 (21.6)21 (16.5)Platelet (×10^4^/μL) \<1044 (35.5)49 (38.9)58 (45.7) ≥1080 (64.5)77 (61.1)69 (54.3) Means (SD)12.0 (5.1)11.5 (4.0)11.4 (4.3)Child-Pugh class^a^ A100 (80.6)104 (82.5)106 (83.5) B24 (19.4)22 (17.5)21 (16.5)HCC Primary111 (89.5)111 (88.1)115 (90.6) First recurrence13 (10.5)15 (11.9)12 (9.4)Treatment Local ablation78 (62.9)81 (64.3)83 (65.4) Surgical resection46 (37.1)45 (35.7)44 (34.6)Number of tumor masses 1104 (83.9)106 (84.1)105 (82.7) 2--319 (15.3)20 (15.9)21 (16.5) ≥41 (0.8)0 (0.0)1 (0.8)Tumor size (cm) \<256 (45.2)55 (43.7)57 (44.9) ≥268 (54.8)71 (56.3)70 (55.1)AFP (ng/mL) ≤1057 (46.0)47 (37.3)45 (35.4) \>1067 (54.0)79 (62.7)82 (64.6) Means (SD)44.8 (152.8)37.3 (76.3)39.4 (82.4)AFP-L~3~ (%) ≤10113 (91.1)116 (92.1)117 (92.1) \>1011 (8.9)10 (7.9)10 (7.9) Means (SD)3.9 (10.1)3.2 (4.8)4.3 (8.3)PIVKA-II (mAU/mL) ≤40115 (92.7)118 (93.7)118 (92.9) \>409 (7.3)8 (6.3)9 (7.1) Means (SD)42.9 (227.0)26.8 (44.1)86.5 (711.3)*BMI* body mass index, *HCC* hepatocellular carcinoma, *AFP* alpha-fetoprotein, *AFP-L3* alpha-fetoprotein L3, *PIVKA-II* protein induced by vitamin K absence or antagonist-II, *SD* standard deviation^a^Severity of hepatic dysfunction evaluated on the scale of Child-Pugh class A to C. The analysis excluded patients with class C hepatic dysfunction

Efficacy {#Sec9}
--------

A total of 377 patients were analyzed (600-mg group: 124, 300-mg group: 126, placebo group: 127). Figure [2](#Fig2){ref-type="fig"} shows 300, 600-mg Kaplan--Meier curves of the 600-mg group, the 300-mg group, and the placebo group for RFS. In the primary comparison, the effect of peretinoin (300 and 600-mg) on RFS compared to that of the placebo was not significant (*P* = 0.434). As shown in the Kaplan--Meier curves, RFS in the 600-mg group during the entire course of the study trended slightly higher than in the other two groups. The proportions of patients with RFS in the 600-mg group, the 300-mg group, and the placebo group, respectively, were 71.9, 63.6, and 66.0 % in year 1, 48.3, 43.4, and 42.3 % in year 2, and 43.7, 24.9, and 29.3 % in Year 3 (Table S2). Hazard ratios for the RFS results of peretinoin 600 mg/day vs. placebo and peretinoin 300 mg/day vs. placebo are shown in Table [2](#Tab2){ref-type="table"}. The risks were comparable in the 300-mg and placebo groups (HR during the entire study period, 1.06; 95 % CI 0.78--1.45; HR after 2 years, 1.19; 95 % CI 0.55--2.60). In contrast, the risk of recurrence after 2 years of randomization in the 600-mg group decreased by 70 % compared to the placebo group (HR during the entire study period, 0.73; 95 % CI 0.51--1.03; HR after 2 years, 0.27; 95 % CI 0.07--0.96). During the study, RFS events were defined as HCC recurrence or death of any cause; there were 53 RFS events observed in patients in the 600-mg group, 80 events in the 300-mg group, and 77 events in the placebo group (Table S2). The analysis of disease-free survival showed comparable results (Fig. S3). Fig. 2Kaplan--Meier curves for recurrence-free survivalTable 2Hazard ratios for recurrence-free survivalHazard ratio (95 % CI)\<1 year1--2 years[\>]{.ul}2 yearsOverall study periodPeretinoin 600 mg/day vs. placebo0.72 (0.45--1.17)0.93 (0.52--1.66)0.27 (0.07--0.96)0.73 (0.51--1.03)Peretinoin 300 mg/day vs. placebo1.11 (0.73--1.70)0.89 (0.50--1.60)1.19 (0.55--2.60)1.06 (0.78--1.45)Hazard ratios for the predetermined periods starting on the day of patient registration and for the entire study period, estimated for peretinoin 600 and 300 mg/day against placebo in a Cox regression analysis with surgical procedure as a covariate. Patients with no events and uncensored patients at the start of predetermined period were included; those with an event and censored patients at the end of predetermined period were censored

Dose--response relationship {#Sec10}
---------------------------

Table [3](#Tab3){ref-type="table"} shows the results of log-rank tests on the three pre-specified comparisons, which were based on the three hypotheses for the dose--response relationship of peretinoin. No significant dose--response relationship was seen in the comparison that tested whether "peretinoin efficacy saturates at 300 mg/day" (*P* = 0.434, the same test applied to the "primary comparison" described previously). When testing whether "peretinoin efficacy increases linearly", no significance was obtained (*P* = 0.079). In contrast, the dose--response relationship was significant in the comparison that tested whether "peretinoin efficacy begins to increase at 600 mg/day" (*P* = 0.023, multiplicity-adjusted *P* = 0.048). Table 3Dose--response relationship of peretinoin for recurrence-free survivalSet of contrast \[Placebo, 300 mg/day, 600 mg/day\]Standardized log-rank score^a^*P*-valueAdjusted *P*-value\[−2, 1, 1\] Efficacy saturates at 300 mg/day−0.7820.434--\[−1, 0, 1\] Efficacy increases linearly−1.7560.079--\[−1, −1, 2\] Efficacy begins to increase at 600 mg/day−2.2690.0230.048^ba^Stratified log-rank test based on surgical procedure^b^Multiplicity between contrasts adjusted by permutation test

Post-hoc subgroup analysis {#Sec11}
--------------------------

The effect of the 600 mg dosage of peretinoin observed in the entire study population was consistent with each subgroup except in patients with tumor size ≥2 cm and Child-Pugh B (Fig. [3](#Fig3){ref-type="fig"}a). There were significant treatment effect interactions with tumor size and Child-Pugh class (*P* = 0.039 and *P* = 0.035, respectively), and the interaction with Child-Pugh class was the largest both in magnitude of the effect size and in statistical significance. Kaplan--Meier curves of the 600-mg group vs. placebo group for RFS in patients with Child-Pugh A are shown in Fig. [3](#Fig3){ref-type="fig"}b. Fig. 3**a** Exploratory, post-hoc, subgroup analysis of hazard ratio for recurrence-free survival. **b** Exploratory, post-hoc, subgroup analysis for recurrence-free survival

Safety {#Sec12}
------

A total of 392 patients were analyzed (600-mg group: 132, 300-mg group: 131, placebo group: 129). The overall incidence of adverse events was 95.5 % (126/132) in the 600-mg group, 93.9 % (123/131) in the 300-mg group, and 90.7 % (117/129) in the placebo group. Common adverse events that occurred in ≥10 % of patients in either the 600 or 300-mg of the treatment groups included ascites, diarrhoea, oesophageal varices, nasopharyngitis, back pain, headache, oedema peripheral, albumin urine present, increased blood pressure and increased transaminases (Table [4](#Tab4){ref-type="table"}). Incidences of these events mainly increased with peretinoin dose. Most of these events were mild or moderate in severity and controllable. The proportion of adverse events which resulted in discontinuation of the study treatment increased with dose: 15.9 % (21/132) in the 600-mg group, 6.9 % (9/131) in the 300-mg group, and 4.7 % (6/129) in the placebo group (*P* = 0.002). These events included onychoclasis, headache, anemia, renal impairment, edema, peripheral edema, and increased transaminases. Table 4Adverse events in safety analysis setAdverse eventsPeretinoinPlacebo *n* = 129600 mg/day *n* = 132300 mg/day *n* = 131TotalSeriousTotalSeriousTotalSeriousNumber (%)Overall incidence126 (95.5)41 (31.1)123 (93.9)39 (29.8)117 (90.7)26 (20.2)Gastrointestinal disorders Ascites21 (15.9)8 (6.1)15 (11.5)1 (0.8)8 (6.2)1 (0.8) Diarrhoea16 (12.1)1 (0.8)10 (7.6)07 (5.4)0 Varices oesophageal13 (9.8)5 (3.8)15 (11.5)7 (5.3)11 (8.5)4 (3.1) Constipation8 (6.1)010 (7.6)05 (3.9)0 Abdominal discomfort8 (6.1)04 (3.1)02 (1.6)0 Stomatitis7 (5.3)05 (3.8)02 (1.6)0 Nausea7 (5.3)02 (1.5)06 (4.7)0 Cheilitis7 (5.3)01 (0.8)00 (0.0)0 Gastritis4 (3.0)07 (5.3)02 (1.6)0 Gastric polyps1 (0.8)012 (9.2)010 (7.8)0Infections and infestations Nasopharyngitis50 (37.9)057 (43.5)1 (0.8)46 (35.7)0 Cystitis9 (6.8)06 (4.6)04 (3.1)0 Urinary tract infection8 (6.1)06 (4.6)3 (2.3)0 (0.0)0Eye disorders Cataract5 (3.8)2 (1.5)7 (5.3)3 (2.3)4 (3.1)2 (1.6)Musculoskeletal and connective tissue disorders Back pain17 (12.9)011 (8.4)010 (7.8)0 Arthralgia7 (5.3)05 (3.8)08 (6.2)0 Muscle spasms3 (2.3)07 (5.3)07 (5.4)0Blood and lymphatic system disorders Anemia7 (5.3)01 (0.8)02 (1.6)0Vascular disorders Hypertension12 (9.1)010 (7.6)04 (3.1)0Respiratory, thoracic and mediastinal disorders Cough4 (3.0)07 (5.3)09 (7.0)0 Upper respiratory tract inflammation2 (1.5)05 (3.8)07 (5.4)0Injury, poisoning and procedural complications Contusion8 (6.1)07 (5.3)07 (5.4)0Nervous system disorders Headache17 (12.9)015 (11.5)011 (8.5)0 Dizziness9 (6.8)05 (3.8)04 (3.1)0General disorders and administration site conditions Edema peripheral16 (12.1)011 (8.4)011 (8.5)0 Pyrexia12 (9.1)2 (1.5)13 (9.9)1 (0.8)8 (6.2)0 Edema10 (7.6)03 (2.3)04 (3.1)0Metabolism and nutrition disorders Diabetes mellitus3 (2.3)1 (0.8)7 (5.3)09 (7.0)0Skin and subcutaneous tissue disorders Pruritus11 (8.3)012 (9.2)09 (7.0)0 Rash7 (5.3)09 (6.9)09 (7.0)0 Nail disorder4 (3.0)07 (5.3)02 (1.6)0Investigations Albumin urine present29 (22.0)014 (10.7)08 (6.2)0 Blood pressure increased26 (19.7)020 (15.3)019 (14.7)1 (0.8) Transaminases increased23 (17.4)010 (7.6)015 (11.6)0 Protein urine present8 (6.1)02 (1.5)00 (0.0)0 Blood urine present5 (3.8)07 (5.3)03 (2.3)0 Gamma-glutamyl transferase increased3 (2.3)05 (3.8)012 (9.3)0Adverse events occurred in ≥5 % of patients in any of the treatment groups in the safety analysis set, as shown in Medical Dictionary for Regulatory Activities (MedDRA) Version 12.0. Adverse events were classified as being serious or non-serious in accordance with definition adopted by the International Conference on Harmonization

The overall incidence of serious adverse events increased with peretinoin dose: 31.1 % (41/132) in the 600-mg group, 29.8 % (39/131) in the 300-mg group, and 20.2 % (26/129) in the placebo group (*P* = 0.048). Seven patients treated with peretinoin died from serious adverse events. They were all aged ≥65 years (including three aged ≥75 years). The baseline Child-Pugh class was A in three patients and B in four. The causes of death varied: three patients in the 600-mg group died of cardiorespiratory arrest, sepsis, and hepatic failure, and four in the 300-mg group died of pneumonia, hepatic failure, sudden death, and diffuse large B-cell lymphoma.

Discussion {#Sec13}
==========

This study could not confirm the efficacy of peretinoin (300 and 600 mg/day) for reducing the recurrence of HCV-HCC. Based on the previous Phase I study \[[@CR26]\], peretinoin was assumed to be effective from the 300 mg/day dose level; thus, this study was designed to compare peretinoin (300 and 600-mg) dosage groups to a placebo group as the primary objective. Unfortunately, the results did not achieve statistical significance. The number of recurrences and the HR observed in the peretinoin 300-mg group were equivalent to that of the placebo group, which indicated the dose level of peretinoin 300 mg/day was ineffective in this patient population. Sample size of the study was determined to test the primary comparison of peretinoin (300 and 600-mg) group vs. placebo group with number of patients in 2:1 ratio. Since there was no statistically significant difference, the comparisons between peretinoin 300-mg or 600-mg to the placebo group were underpowered.

The gene expression pattern in the liver before and after peretinoin treatment was examined in a clinical pharmacological study performed in humans simultaneously with this study. Genes expected to result in inhibition of recurrence, including retinoid-induced genes, interferon- and tumor suppressor-related genes, and hepatocyte differentiation genes, were among the genes that changed markedly before and after treatment with 600 mg/day. However, there was little change or no change in expression of these genes with treatment at 300 mg/day \[[@CR27]\]. Consequently, while it was assumed that non-clinical studies and pharmacokinetic results showed that treatment of 300 mg/day elicited sufficient medicinal action, the above results of treatment with 300 mg/day in humans shows insufficient change in gene expression, and as such, probably does not confirm the previous result.

The optimal dose of peretinoin was found to be 600 mg/day, and it was possibly effective, particularly after 2 years from curative treatment. A previous study reported that the overall HR for peretinoin 600 mg/day vs. placebo was 0.31 (95 % CI 0.12--0.78) \[[@CR21]\]. This result is comparable to the HR after 2 years (0.27; 95 % CI 0.07--0.96) in our study. While the previous study evaluated recurrence of only de novo carcinogenesis (second primary HCC), this study evaluated both intrahepatic metastasis and de novo carcinogenesis. However, multicentric de novo carcinogenesis is the common cause of recurrence after 2 years \[[@CR11], [@CR12]\].

Adverse reactions associated with other retinoids \[[@CR26]\] (e.g., mucocutaneous symptoms such as cheilitis and peeling skin, abnormal lipid metabolism, musculoskeletal disorders, and ocular symptoms) occurred infrequently in patients treated with peretinoin. Ascites and increased blood pressure were specific to peretinoin. Blood pressure should be periodically monitored before and during treatment with peretinoin and controlled with antihypertensives as appropriate. Seven patients died from various adverse events. Associations between peretinoin and these adverse events were undeterminable, because all seven patients who died from adverse events were aged ≥65 years, and four among them had Child-Pugh B hepatic impairment. Thus, age and advanced hepatic impairment could have been the causative factor rather than the treatment. The fact that 70 % of study patients were aged ≥65 years attests to the overall tolerability of peretinoin in elderly patients. The Child-Pugh class could also affect peretinoin efficacy. The guidelines for clinical studies of HCC recommend inclusion of patients with Child-Pugh A in clinical trials because death from cirrhosis in patients with Child-Pugh B or C could mask the efficacy of treatment \[[@CR28]\]. The proportion of patients with Child-Pugh A was about 80 % in this study. Subgroup analysis revealed that the effect of peretinoin 600-mg in Child-Pugh A patients was significant (HR, 0.60; 95 % CI 0.41--0.89), even though these analyses were post-hoc and exploratory. Recently, a confirmatory peretinoin study was initiated and will be focused on Child-Pugh A patients.

Systemic chemotherapy, immunotherapy, and interferon have not been established as a standard treatment for the prevention of HCV-HCC \[[@CR13]--[@CR15]\]. Through its antiviral action, interferon delays the progression of cirrhosis and hepatic impairment and prolongs survival (pooled risk ratio, 0.65; 95 % CI 0.52--0.80). However, it does not significantly reduce recurrence (pooled risk ratio, 0.86; 95 % CI 0.76--0.97) \[[@CR13]\]. Peretinoin was previously shown to decrease the risk of recurrence of de novo carcinogenesis by about 70 % \[[@CR20]\], and this result was reproduced in this study. Considerably prolonged survival was observed (risk ratio, 0.3; 95 % CI 0.1--0.8) \[[@CR21]\].

A previous study revealed that 25 % of adverse reactions to interferon were severe, resulting in treatment discontinuation or dose reduction \[[@CR13]\]. While safety issues prevent the use of interferon in elderly patients \[[@CR29], [@CR30]\], this study indicated that peretinoin was well tolerated by such elderly patients.

One limitation of this study is that the median follow-up period of 2.5 years may be considered short. Since recurrences due to de novo carcinogenesis peak after 4 years postoperatively \[[@CR11]\], the reduction of de novo carcinogenesis due to peretinoin may have been more accurately reflected with a longer follow-up period. However, the sample size at 2 years in this study (about 40 patients in each group) was comparable to the sample size of a previous study \[[@CR21]\] and adequate to statistically evaluate the efficacy of peretinoin. Future studies should, however, include longer follow-up analysis if feasible.

In this study, the superiority of peretinoin (300 and 600-mg) to placebo could not be evaluated. Peretinoin 600 mg/day was found to be the optimal dose, and it could possibly reduce the recurrence of HCV-HCC. Although the HR for the RFS in the peretinoin 600 mg/day vs. placebo was not statistically significant for the entire study period, the significant reduction by \>70 % in recurrence after 2 years is clinically meaningful and consistent with previous study results \[[@CR21]\]. Further confirmatory studies on Child-Pugh class A patients are worth conducting and would continue to ensure the efficacy of the peretinoin 600 mg/day regimen and thoroughly explore its safety.
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